Detalhe da pesquisa
1.
Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.
Bioorg Med Chem Lett
; 66: 128726, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35413416
2.
Discovery of DS34942424: An orally potent analgesic without mu opioid receptor agonist activity.
Bioorg Med Chem
; 28(21): 115714, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065431
3.
Discovery of a novel bicyclic compound, DS54360155, as an orally potent analgesic without mu-opioid receptor agonist activity.
Bioorg Med Chem Lett
; 29(23): 126748, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31676224
4.
Discovery of conolidine derivative DS39201083 as a potent novel analgesic without mu opioid agonist activity.
Bioorg Med Chem Lett
; 29(15): 1938-1942, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31147104
5.
Synthesis and biological evaluation of novel imidazol-1-ylacetic acid derivatives as non-brain penetrant bombesin receptor subtype-3 (BRS-3) agonists.
Bioorg Med Chem Lett
; 26(17): 4205-10, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27491709
6.
Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor.
Bioorg Med Chem
; 21(11): 3175-96, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23598247
7.
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
J Med Chem
; 66(1): 695-715, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36572866
8.
Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist.
Bioorg Med Chem Lett
; 22(4): 1788-92, 2012 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22264485
9.
Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P3-sparing S1P1 agonists.
Bioorg Med Chem Lett
; 22(9): 3083-8, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22487179
10.
Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Breast Cancer
; 24(4): 615-623, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28050738
11.
Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.
Eur J Med Chem
; 51: 92-8, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22405291
12.
Short-step and scalable synthesis of (+/-)-cytoxazone.
Biosci Biotechnol Biochem
; 69(1): 145-8, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15665479